Journal
PHARMACEUTICS
Volume 15, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics15010047
Keywords
cutaneous T-cell lymphoma; dermatology; mycosis fungoides; photodynamic therapy; phototherapy; porphyrins; cancer; cutaneous B-cell lymphoma; pseudolymphoma
Categories
Ask authors/readers for more resources
Topical photodynamic therapy (PDT) is a promising treatment option for cutaneous lymphomas, with good tolerability and cosmetic outcomes. However, its mechanism of action and efficacy in treating lymphoproliferative diseases are still not well understood. Further clinical trials are needed to determine the optimal treatment protocol.
Topical photodynamic therapy (PDT) is a non-invasive treatment modality frequently used in dermatology to treat superficial skin cancers but also some inflammatory or infectious dermatoses. PDT appears a more and more promising therapeutic option also for cutaneous lymphomas, either of T- or B-cell origin. It is a well-tolerated treatment and has excellent cosmetic outcomes, less side effects compared to other therapies (steroids, surgery, radiotherapy, and so on), no particular contraindications, and is easily repeatable in case of relapses. However, how PDT works in the treatment of cutaneous lymphoproliferative diseases is poorly understood and the literature data are still controversial. Further randomized, controlled clinical trials involving a greater number of patients and centers with a long follow-up are necessary to assess the efficacy of PDT and establish a unique standardized treatment protocol in relation to the lymphomatous disease and the type, thickness, and location of the lesions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available